Cadrenal Therapeutics CVKD
NASDAQ CVKD
$1.45 +0.01 (+0.69%)
At close: Nov 11, 2026 · 4:00 PM EST

Cadrenal Therapeutics (CVKD) Return on Capital Employed [ROCE] (2023 - 2026)

Updated

Cadrenal Therapeutics' Return on Capital Employed [ROCE] was -439.89% in Q2 2026, down 242.84 percentage points from -197.05% a year earlier.

Analysis

Cadrenal Therapeutics (CVKD) Return on Capital Employed [ROCE] (2023 - 2026) Analysis & Trends

For FY2023, Return on Capital Employed [ROCE] at Cadrenal Therapeutics came in at -199.72%.

  • The Q2 2026 figure marks the lowest quarterly Return on Capital Employed [ROCE] in data going back to Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Cadrenal Therapeutics 557,746.58 -12.06 Mn - -427.15%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -427.15%
Mar 31, 2026 -476.30%
Dec 31, 2025 -513.95%
Sep 30, 2025 -398.73%
Jun 30, 2025 -272.41%
Mar 31, 2025 -182.45%
Dec 31, 2024 -232.34%
Sep 30, 2024 -209.03%
Jun 30, 2024 -138.45%
Mar 31, 2024 -74.89%
Dec 31, 2023 -94.37%
Sep 30, 2023 -126.79%
Jun 30, 2023 -199.53%
Mar 31, 2023 -302.06%
API Access

Cadrenal Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=CVKD&period=max&api_key=YOUR_API_KEY